CSV October 23, 2023 through October 24, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUTICASONE IM		*USP41–NF36*	1836	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the *Tailing*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PROPIONATE INHALATION POWDER	PURITIES/*Organic Impurities*/*System suitability*							*factor*: Change NLT 1.3 to: NMT 1.3
GLUTARAL CONCENTRATE	ASSAY/*Procedure*	*USP41–NF36*	1960	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list in *Analysis*: Change *W* = weight of Concentrate taken (g) to: *W* = nominal weight of glutaral taken (g)
AZEOTROPIC ISOPROPYL ALCOHOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	2257	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of USP 2-Propanol System Suitability RS: Change It contains 0.1% of each of the following: ethyl ether, acetone, isopropyl alcohol, diisopropyl ether, 1-propanol, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
METOPROLOL TARTRATE	CHEMICAL INFORMATION	*USP41–NF36*	2712	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	2-butanol. to: It is a mixture of the following: ethyl ether (0.1%), acetone (0.1%), diisopropyl ether (0.1%), 1-propanol (0.1%), 2-butanol (0.1%), and isopropyl alcohol (99.5%). Line 4: Change (±)-1-(Isopropyl amin o)-3-[*p* -(2-methoxyethy l)phenoxy]-2-pr opanol l-(+)-tartrate (2:1) (salt); 1-(Isopropylami no)-3-[*p* -(2-methoxyethy l)phenoxy]-2-pr opanol (2:1) *dextro*-tartrate salt

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (±)-1-(Isopropylamino)-3-[*p*-(2-methoxyethyl)phenoxy]-2-propanol (+)-tartrate (2:1) (salt); 1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol L-tartrate
AMLODIPINE AND ATORVASTATIN TABLETS	DEFINITION	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 4: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$)
AMLODIPINE AND ATORVASTATIN TABLETS	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the second Calculate statement in *Analysis*: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$)
AMLODIPINE AND ATORVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the second Calculate statement in *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$) AND In *Tolerances*: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$)
ACAMPROSATE CALCIUM	IMPURITIES/*Limit of Acamprosate Related Compound A*	*First Supplement to USP41–NF36*	8263	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list in *Analysis*: Change C_S = concentration of USP Acamprosate Calcium Related Compound A RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Acamprosate Related Compound A RS in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NAPROXEN SODIUM TABLETS	IM PURITIES/*Organic Impurities*	*First Supplement to USP41–NF36*	8363	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	*Standard solution* (µg/mL) In the *System suitability solution*: Change 0.5 mg/mL of USP Naproxen Sodium RS and 0.5 µg/mL of USP Naproxen Related Compound A RS in *Diluent*, from *Standard stock solution 1* and *Standard stock solution 2*, respectively to: 0.5 µg/mL of USP Naproxen Related Compound A RS from *Standard stock solution 2* and 0.5 mg/mL of USP Naproxen Sodium RS in *Diluent*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OCTOCRYLENE	SPECIFIC TESTS/*Acidity*	*First Supplement to USP41–NF36*	8379	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of *Acceptance criteria*: Change NMT 0.18 mL of *Titrant* is required to: NMT 0.18 mL of *Titrant*/g is required
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	IM PURITIES/*Organic Impurities*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In the variable definition list in *Analysis*: Change C_U = nominal concentration of the *Sample solution* (mg/mL) to: C_U = nominal concentration of the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(mg/mL) [Note—Disregard any peak less than 0.1%.]
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 8*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the variable definition list in *Analysis*: Change C_S = concentration of oxybutynin chloride in the *Standard solution* (mg/mL) to: C_S = concentration of USP Oxybutynin Chloride RS in the *Standard solution* (mg/mL)
LIDOCAINE	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the new *USP-NF* ONLINE platform only. Line 2 of *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid, AND Line 2 of *Sample solution*: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid,
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	ASSAY/ *Procedure*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In *System suitability*: Add [Note—The relative retention times for oxybutynin and oxybutynin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								related compound A are about 1.0 and 1.6, respectively.]
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution Test 1*	*USP41–NF36*	3157	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the *Analysis*: Change Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2}) \times V \times (100/L)$ to: Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2}) \times V \times (100/L) \times D$ AND In the variable definition list in *Analysis*: Add D = dilution factor for the *Sample solution*, 2
AMOXICILLIN	IDENTIFICATION/*A.*	*First Supplement to USP41–NF36*	Online	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Line 1: Change *Infrared Absorption*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<197> to: *Infrared Absorption <197K>*
RITONAVIR CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*Revision Bulletin (Official April 01, 2018)*	Online	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Row 1 of Column 3 of *Table 1*: Change *Tolerances (Q)* to: *Tolerances* AND Row 3 of Column 3 of *Table 1*: Change NLT 80% to: NLT 80% (*Q*)
ZOLMITRIPTAN TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official November 01, 2017)*	Online	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of *Analysis*: Change *Sample*: *Sample solution* to: *Samples*: *Standard solution* and *Sample solution*
PURE STEAM	ADDITIONAL R	*USP41–NF36*	4348	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second*	Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	EQUIREMENTS						*Supplement to USP41–NF36*	• *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
STERILE PURIFIED WATER	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4348	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
PURIFIED WATER	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4347	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
STERILE WATER FOR IRRIGATION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4347	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
STERILE WATER FOR INJECTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4346	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
STERILE WATER FOR	ADDITIONAL REQUIREMENT	*USP41–NF36*	4346	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to*	Delete • *USP*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INHALATION	S						*USP41–NF36*	*Reference Standards <11>* USP 1,4-Benzoquinone RS
WATER FOR HEMODIALYSIS	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4345	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
WATER FOR INJECTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4345	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS
VINORELBINE INJECTION	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP41–NF36*	4326	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Relative standard deviation*: Change NLT 2.0%, *Standard solution* to: NMT 2.0%, *Standard solution*
RIZATRIPTAN BENZOATE	ADDITIONAL REQUIREMENTS/*USP*	*USP41–NF36*	3662	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 6 of USP Rizatriptan Benzoate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Reference Standards <11>							System Suitability Mixture RS: Change 269.34) to: 269.35)
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE ACETATE OPHTHALMIC SUSPENSION	*Assay for hydrocortisone acetate*	*USP41–NF36*	2904	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1: Change Proceed with Ophthalmic Suspension as directed in the *Assay* under *Hydrocortisone Acetate Injectable Suspension*. to: *Standard prep aration*—Prepare as directed for *Assay for Steroids <351>*, *Standard Preparation*, using USP Hydrocortisone Acetate RS. *Assay prep*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								aration—Transfer to a separator an accurately measured volume of Ophthalmic Suspension, equivalent to about 50 mg of hydrocortisone acetate, and dilute with water to about 15 mL. Extract with four 25-mL portions of chloroform, filtering each portion through chloroform-washed cotton into a 250-mL volumetric flask. Add chloroform to volume, and mix. Pipet 10 mL of this solution into a 100-mL volumetric flask, add chloroform

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to volume, and mix. Pipet 10 mL of the resulting solution into a gl ass-stoppered, 50-mL conical flask, evaporate the chloroform on a steam bath just to dryness, cool, and dissolve the residue in 20.0 mL of alcohol. *Proce dure*—Proceed as directed for *Assay for Steroids <351>*, *Procedure*. Calculate the quantity, in mg, of hydrocortisone acetate ($C_{23}H_{32}O_6$) in each mL of Ophthalmic Suspension taken by the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								formula: $5(C/V)(A_U/A_S)$ in which V is the volume, in mL, of Ophthalmic Suspension taken; and the other terms are defined therein.
LEVODOPA	IM PUR ITIES/*Organic Impurities*	*USP41–NF36*	2392	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Footnote a of *Table 1*: Change 3-(3,4,6-Trihydroxyphenyl)alanine. to: 3-(3,4,6-Trihydroxyphenyl)alanine; also known as 3-(2,4,5-Trihydroxyphenyl)-L-alanine.
GUAIFENESIN	IM PUR ITIES/*Organic Impurities*	*USP41–NF36*	2001	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	In the equation in *Analysis*: Change Result = $(r_U/r_S) \times (1/F) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Add to the variable list: C_S = concentration of guaifenesin in the *Diluted sample solution* C_U = concentration of guaifenesin in the *Sample solution*
DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	1447	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of USP Ethinyl Estradiol Related Compound B RS: Change 19-Nor-17?-pregna-1,3,5(10),9(11)-tetraen-20-yne-3,17-diol. $C_{20}H_{22}O_2$ 294.39 to: 19-Nor-17?-pregna-1,3,5(10),9(11)-tetraen-20-yne-3,17-diol monohydrate. C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{20}H_{22}O_2 \cdot H_2O$ 312.40
NAPROXEN TABLETS	IM PURITIES/*Organic Impurities*	*USP41–NF36*	2865	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 3 of *System suitability solution*: Change 0.5 mg/mL of USP Naproxen RS and 0.5 µg/mL of USP Naproxen Related Compound A RS in *Diluent*, from *Standard stock solution 1* and *Standard stock solution 2*, respectively to: 0.5 µg/mL of USP Naproxen Related Compound A RS from *Standard stock solution 2* and 0.5 mg/mL of USP Naproxen RS in *Diluent*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CYCLOPHOSPHAMIDE	ASSAY/ *Procedure*	*USP41–NF36*	1123	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	In the variable definition in *Analysis*: Change C_S = concentration of USP Cyclophosphamide RS in the *Standard solution* (mg/mL). [Note—Concentration is calculated on the anhydrous basis.] C_U = concentration of Cyclophosphamide in the *Sample solution* (mg/mL). [Note—Nominal concentration is calculated on the anhydrous basis.] to: C_S = concentration of USP Cyclophosphamide RS in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Standard solution* (mg/mL) C_U = concentration of Cyclophosphamide in the *Sample solution* (mg/mL)
LORAZEPAM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	2474	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 3 of USP Lorazepam Related Compound B RS: Change 266.13 to: 266.12 AND Line 4 of USP Lorazepam Related Compound C RS: Change 303.15 to: 303.14 AND Line 4 of USP Lorazepam Related Compound D

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS: Change 319.15 to: 319.14
LOXAPINE SUCCINATE	IM PURITIES/*Organic Impurities/Procedure*	*USP41–NF36*	2486	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	In the variable definition list in *Analysis*: Add F = relative response factor (see *Impurity Table 1*)
MEPIVACAINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	2580	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of Bupivacaine Related Compound B: Change *N*-(2,6-Dimethylphenyl)piperidine-2-carboxamide. $C_{14}H_{20}N_2O$ 232.32 to: *N*-(2,6-Dimethylphenyl)piperidine-2-carboxamide hydrochloride. $C_{14}H_{20}N_2O \cdot HCl$ 268.79
METHADONE	ASSAY/	*USP41–NF36*	2628	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second*	In the *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE INJECTION	*Procedure*						*Supplement to USP41–NF36*	Change Result = $(R_U/R_S) \times W \times 100$ to: Result = $(R_U/R_S) \times W$
PIOGLITAZONE AND GLIMEPIRIDE TABLETS	IMPURITIES/*Organic Impurities: Glimepiride*	*USP41–NF36*	3314	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Change *Table 3* to: *Table 4* AND Change *Table 4* to: *Table 5* AND Line 1 of *Mobile phase*: Change *Table 3* to: *Table 4* AND In the variable definition list in *Analysis*: Change *F* = relative response factor for each impurity (see

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Table 4) to: *F* = relative response factor for each impurity (see *Table 5*) AND Line 1 of *Acceptance criteria*: Change *Table 4* to: *Table 5*
INSULIN ASSAYS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	6054	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Delete USP Insulin RS
TEST FOR 1,6-ANHYDRO DERIVATIVE FOR ENOXAPARIN SODIUM	PROCEDURES/*Procedure*	*USP41–NF36*	6108	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of *Reduction suitability test*: Change 0.02%. to: 0.02.
NIFEDIPINE EXTENDED-RELEASE	PERFORMANCE TESTS/	*First Supplement to USP41–NF36*	8369	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Standard stock solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	*Dissolution <711>/Test 5*							Change 50 mg of USP Nifedipine RS in *Diluent A* and water (50:50) to: 0.50 mg/mL of USP Nifedipine RS prepared as follows. Transfer a suitable amount of USP Nifedipine RS to an appropriate volumetric flask. Dissolve in 50% of the flask volume of *Diluent A*. Dilute with water to volume. AND Line 1 of *Instrumental condit ions/Analytical wavelength*: Change 238 nm to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VITAMIN D ASSAY	ASSAY/ *Procedure 8*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	338 nm Line 1 of *Aqueous potassium hydroxide solution*: Change 800 mg to: 800 g
BUMETANIDE TABLETS	IM PUR ITIES/*Organic Impuri ties/ Chromatographi c system*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Developing solvent system*: Change Methanol, cyclohexane, methanol, glacial acetic acid, and chloroform (2.5: 10: 10: 80) to: Methanol, cyclohexane, glacial acetic acid, and chloroform (2.5: 10: 10: 80)
ISOLEUCINE	IM PUR ITIES/*Related*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Compounds							ONLINE platform only. Line 1 of *Standard solution*: Change USP L-Leucine RS to: USP L-Isoleucine RS
TRIAMTERENE	ADDITIONAL REQUIREMENTS	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF*
								ONLINE platform only. Line 4 of *USP Reference Standards* <*11*>: Change USP Doxazosin Related Compound A RS to: USP Triamterene Related Compound A RS
TRANEXAMIC	SPECIFIC	*First*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second*	This erratum

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ACID INJECTION	TESTS	*Supplement to USP41–NF36*					*Supplement to USP41–NF36*	applies to the new *USP-NF* ONLINE platform only. Change *Dissolution* <*711*>: Meets the requirements to: *Sterility Tests* <*71*>: Meets the requirements
GLYCERYL TRICAPRYLATE	ASSAY/*Content of Triglycerides*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Line 1 of *System suitability solution*: Change 20 mUSP Glyceryl Monocaprylate RSUSP Glyceryl Monocaprylate RSg/mL each of 1-monooctanoyl-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								rac-glycerol and 1-monodecanoyl-rac-glycerol in tetrahydrofuran to: 20 mg/mL each of 1-monooctanoyl-rac-glycerol and 1-monodecanoyl-rac-glycerol in tetrahydrofuran
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION	IMPURITIES/*Organic Impurities: Dorzolamide Hydrochloride*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. In the first variable definition list in *Analysis*: Change C_S = concentration of USP Doxazosin Related Compound D RS in the *Standard solution* (mg/mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: C_S = concentration of USP Dorzolamide Related Compound D RS in the *Standard solution* (mg/mL) AND In the second variable definition list in *Analysis*: Change C_S = concentration of USP Doxazosin Related Compound B RS in the *Standard solution* (mg/mL) to: C_S = concentration of USP Dorzolamide

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORDINARY IMPURITIES	KEY FOR VISUALIZATION TECHNIQUES	*USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Related Compound B RS in the *Standard solution* (mg/mL) This erratum applies to the new *USP-NF* ONLINE platform only. Change 3. *Solution A*–Mix 850 mg of bismuth subnitrate with 40 mL of water and 10 mL of glacial acetic acid. 4. *Solution B*–Dissolve 8 g of potassium iodide in 20 mL of water. Mix A and B together to obtain a Stock Solution which can be stored for several months

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in a dark bottle. Mix 10 mL of the Stock Solution with 20 mL of glacial acetic acid, and dilute with water to make 100 mL, to prepare the spray reagent. to: 3. *Solution A*–Mix 850 mg of bismuth subnitrate with 40 mL of water and 10 mL of glacial acetic acid. *Solution B*–Dissolve 8 g of potassium iodide in 20 mL of water. Mix A and B together to obtain a Stock Solution which can be stored for several months

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in a dark bottle. Mix 10 mL of the Stock Solution with 20 mL of glacial acetic acid, and dilute with water to make 100 mL, to prepare the spray reagent. AND Update list numbers 5–23 to: 4–22

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21

- Page 22
- …
- Next page Next ›
- Last page Last »